Horsham, Pennsylvania – Johnson & Johnson is investing over $1 billion to build a new cell therapy manufacturing facility in Pennsylvania, bolstering the company’s commitment to innovative cancer treatments and expanding its production capacity for potentially life-saving therapies. The new facility, announced February 18, 2026, will focus on the production of cell therapies, a rapidly growing field of medicine that harnesses the power of a patient’s own immune system to fight cancer.
This substantial investment underscores Johnson & Johnson’s position as a global leader in healthcare and its dedication to addressing some of the most challenging diseases facing humanity. The company, which reported a net revenue split of 64.1% from pharmaceutical products and 35.9% from medical devices and diagnostics in 2024, is strategically expanding its capabilities in cell therapy to meet the increasing demand for these advanced treatments. As of the end of 2024, Johnson & Johnson operated 64 manufacturing facilities across the globe, including 23 in the United States.
Expanding Cell Therapy Capabilities
Cell therapy involves modifying a patient’s own immune cells to recognize and destroy cancer cells. This personalized approach to treatment has shown remarkable success in certain blood cancers, and researchers are actively exploring its potential in solid tumors and other diseases. The new Pennsylvania facility will be equipped with state-of-the-art technology to support the entire cell therapy manufacturing process, from cell collection and modification to final product formulation and quality control.
The decision to locate the facility in Pennsylvania reflects the state’s growing biotechnology sector and its skilled workforce. The investment is expected to create hundreds of high-paying jobs in the region, contributing to the local economy and fostering innovation. Johnson & Johnson’s commitment to advanced manufacturing techniques, including the use of digital twins and AI-driven predictions to optimize supply chains, will be integral to the operation of the new facility.
Recent Acquisitions and Innovations
Johnson & Johnson’s investment in cell therapy manufacturing comes on the heels of several strategic acquisitions and advancements in the field. In May 2024, the German Federal Cartel Office approved Johnson & Johnson’s acquisition of Shockwave Medical, a company specializing in technologies for treating cardiovascular diseases, for approximately $13.1 billion. This acquisition expands Johnson & Johnson’s portfolio of innovative medical technologies and strengthens its position in the cardiovascular market. The Federal Cartel Office noted that while Shockwave Medical had relatively low revenues in Germany at the time of the acquisition, it was active in significant growth markets.
Johnson & Johnson has been at the forefront of developing cutting-edge technologies for treating coronary artery disease, such as the Shockwave system, which utilizes ultrasonic acoustic pressure waves. The company’s Impella heart pump, developed by Thorsten Siess, Ph.D., has helped over 400,000 patients recover from heart injuries since its introduction 25 years ago. These innovations demonstrate Johnson & Johnson’s long-standing commitment to improving patient outcomes and advancing medical science.
Addressing Cardiovascular Disease
Cardiovascular disease remains a leading cause of death worldwide, and Johnson & Johnson is actively working to address this global health challenge. The company’s website details its efforts to develop innovative medical technologies and therapeutics for treating conditions such as stroke and atrial fibrillation. The new cell therapy facility, while focused on cancer treatment, represents a broader investment in advanced therapies that have the potential to transform healthcare.
The company’s research extends to improving stroke care, with innovative research underway to make treatment more effective and facilitate neurovascular patients lead longer, fuller lives. Johnson & Johnson also supports research into the treatment of atrial fibrillation (AFib), exploring the roles of pulmonary vein isolation (PFA) and radiofrequency ablation (RFA) in cardiac ablation procedures.
Looking Ahead
The construction of the new cell therapy manufacturing facility in Pennsylvania is expected to be completed in the coming years. Johnson & Johnson will continue to invest in research and development, seeking to expand the applications of cell therapy and bring new treatments to patients in necessitate. The company’s commitment to innovation, coupled with its global reach and manufacturing expertise, positions it as a key player in the future of healthcare. The next major milestone will be the completion of site preparation and the commencement of building construction, anticipated in late 2026.
What are your thoughts on Johnson & Johnson’s investment in cell therapy? Share your comments below and help us continue the conversation.
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical or investment advice. Consult with a qualified healthcare professional or financial advisor for any health concerns or before making any decisions related to your health or finances.
